España
Acceder

Farmas USA

136K respuestas
Farmas USA
86 suscriptores
Farmas USA
Página
12.326 / 17.034
#98603

Re: Farmas USA

Top 25
anaramos

ITEK

Cagada estrepitosa de fase III. Funciona peror que el placebo.

http://www.businesswire.com/news/home/20170103005518/en/

CLVS

Colocación
initiates a $175M public offering of common stock. Price, volume and terms have yet to be announced. Net proceeds will fund general corporate purposes including the U.S. launch of Rubraca
http://seekingalpha.com/news/3233033-clovis-readies-equity-offering

KITE

Nueva IND for KITE-718, an Investigational Next Generation T-Cell Receptor (TCR) Therapy Targeting Cancer Antigens MAGE A3 & MAGE A6

ABEO

Fármaco huérfano UE Juvenile Batten Disease

http://finance.yahoo.com/news/abeona-therapeutics-receives-orphan-drug-124300793.html?soc_src=social

«Después de nada, o después de todo/ supe que todo no era más que nada.»

#98605

Re: Farmas USA

Sin que sirve de precedente, me gusta el argumento contra-intuitivo del punto #4...

"Biotech investor sentiment: It sucks. That's actually bullish because basically anything positive is upside at this point."

#98606

Re: Farmas USA

Leyendo el PR de PixarBio, entiendo que es una OPA hostil del ex-CEO de InVivo...

1.- En la web de InVivo no sé recoge la oferta.
2.- El PR pega una bonita rajada del board y CEO actuales.

https://pixarbio.com/time-make-us-pharma-great-combining-two-frank-reynolds-founded-pharmas-pixarbio-corp-otcqxpxrb-invivo-therapeutics-nasdaqnviv-77000000-stock-offe/

"It’s been over 3.5 years since I resigned as CEO of InVivo Therapeutics Corporation, to found PixarBio Corporation (PXRB) in August 2013. It’s clear that 2013-2017 have not been great years for the NVIV CEO & the NVIV Board of Directors. The round of recent MAJOR exits makes it a perfect time to keep the required exits for success going. It’s time to focus on shareholder value, and REAL change at NVIV. I founded InVivo Therapeutics over 11 years ago but the last 3.5 years have been a black hole for investor’s money, and the NVIV team has had a real dead spot in innovation failing in the area of shareholder value creation, so it’s time for real change", said PixarBio CEO Frank Reynolds.

NVIV PXRB